tetano
Editor, Senior Moderator
Vaccine. 2015 Apr 10. pii: S0264-410X(15)00464-8. doi: 10.1016/j.vaccine.2015.04.011. [Epub ahead of print]
[h=1]Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.[/h] ?rtqvist ?[SUP]1[/SUP], Bennet R[SUP]2[/SUP], Hamrin J[SUP]2[/SUP], Rinder MR[SUP]3[/SUP], Lindblad H[SUP]4[/SUP], ?hd JN[SUP]5[/SUP], Eriksson M[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Immunological studies have indicated that the effectiveness of AS03 adjuvanted monovalent influenza A(H1N1)pdm09 vaccine (Pandemrix[SUP]?[/SUP]) may be of longer duration than what is seen for non-adjuvanted seasonal influenza vaccines. Sixty-nine percent of children 6 months-18 years of age in Stockholm County received at least one dose of Pandemrix[SUP]?[/SUP] during the 2009 pandemic. We studied the effectiveness of the vaccine during the influenza seasons 2010-2011 and 2012-2013 in children hospitalized with virologically confirmed influenza. The season 2011-2012 was not included, since influenza A(H3N2) was the predominant circulating strain.
[h=4]METHODS:[/h] In a retrospective case-control study using a modified test-negative design we compared the percentage vaccinated with Pandemrix[SUP]?[/SUP] among children diagnosed with influenza A(H1N1)pdm09 (cases), with that of those diagnosed with influenza A(H3N2) or influenza B (controls) during the two seasons. We excluded children born after July 1, 2009, since only children who were 6 months of age or older received the pandemic vaccine in October-December 2009.
[h=4]RESULTS:[/h] During the 2010-2011 season, 3/16 (19%) of children diagnosed with influenza A(H1N1)pdm09, vs. 32/41 (78%) of those with influenza A(H3N2) or influenza B had been vaccinated with Pandemrix[SUP]?[/SUP] in 2009. The odds ratio, after adjustment for sex, age and underlying diseases, for becoming a case when vaccinated with Pandemrix[SUP]?[/SUP] was 0.083 (95%CI 0.014, 0.36), corresponding to a VE of 91.7%. During the season 2012-2013, there was no difference between the two groups; 59% of children diagnosed with influenza A(H3N2)/B and 60% of those with influenza A(H1N1)pdm09 had been vaccinated with Pandemrix[SUP]?[/SUP] in 2009.
[h=4]CONCLUSION:[/h] The AS03 adjuvanted monovalent influenza A(H1N1) pdm09 vaccine (Pandemrix[SUP]?[/SUP]) was effective in preventing hospital admission for influenza A(H1N1)pdm09 in children during at least two seasons.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Children; Effectiveness; Long term; Pandemic; Vaccination
PMID: 25869891 [PubMed - as supplied by publisher]
[h=1]Long term effectiveness of adjuvanted influenza A(H1N1)pdm09 vaccine in children.[/h] ?rtqvist ?[SUP]1[/SUP], Bennet R[SUP]2[/SUP], Hamrin J[SUP]2[/SUP], Rinder MR[SUP]3[/SUP], Lindblad H[SUP]4[/SUP], ?hd JN[SUP]5[/SUP], Eriksson M[SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Immunological studies have indicated that the effectiveness of AS03 adjuvanted monovalent influenza A(H1N1)pdm09 vaccine (Pandemrix[SUP]?[/SUP]) may be of longer duration than what is seen for non-adjuvanted seasonal influenza vaccines. Sixty-nine percent of children 6 months-18 years of age in Stockholm County received at least one dose of Pandemrix[SUP]?[/SUP] during the 2009 pandemic. We studied the effectiveness of the vaccine during the influenza seasons 2010-2011 and 2012-2013 in children hospitalized with virologically confirmed influenza. The season 2011-2012 was not included, since influenza A(H3N2) was the predominant circulating strain.
[h=4]METHODS:[/h] In a retrospective case-control study using a modified test-negative design we compared the percentage vaccinated with Pandemrix[SUP]?[/SUP] among children diagnosed with influenza A(H1N1)pdm09 (cases), with that of those diagnosed with influenza A(H3N2) or influenza B (controls) during the two seasons. We excluded children born after July 1, 2009, since only children who were 6 months of age or older received the pandemic vaccine in October-December 2009.
[h=4]RESULTS:[/h] During the 2010-2011 season, 3/16 (19%) of children diagnosed with influenza A(H1N1)pdm09, vs. 32/41 (78%) of those with influenza A(H3N2) or influenza B had been vaccinated with Pandemrix[SUP]?[/SUP] in 2009. The odds ratio, after adjustment for sex, age and underlying diseases, for becoming a case when vaccinated with Pandemrix[SUP]?[/SUP] was 0.083 (95%CI 0.014, 0.36), corresponding to a VE of 91.7%. During the season 2012-2013, there was no difference between the two groups; 59% of children diagnosed with influenza A(H3N2)/B and 60% of those with influenza A(H1N1)pdm09 had been vaccinated with Pandemrix[SUP]?[/SUP] in 2009.
[h=4]CONCLUSION:[/h] The AS03 adjuvanted monovalent influenza A(H1N1) pdm09 vaccine (Pandemrix[SUP]?[/SUP]) was effective in preventing hospital admission for influenza A(H1N1)pdm09 in children during at least two seasons.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] Children; Effectiveness; Long term; Pandemic; Vaccination
PMID: 25869891 [PubMed - as supplied by publisher]